|
ホシノ ジュンイチ
Hoshino Junichi
星野 純一 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Patient characteristics and treatment efficacy after switching to hypoxia-inducible factor-prolyl hydroxylase inhibitors from erythropoiesis-stimulating agents in non-dialysis-dependent chronic kidney disease patients: the Reach-J CKD cohort study. |
| 掲載誌名 | 正式名：BMC nephrology 略 称：BMC Nephrol ISSNコード：14712369/14712369 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.online |
| 著者・共著者 | Yamagata Kunihiro, Ohigashi Tomohiro, Saito Chie, Kai Hirayasu, Tsunoda Ryoya, Okubo Reiko, Kondo Masahide, Ishii Haruka, Inuzuka Masami, Harada Kenji, Narita Ichiei, Okada Hirokazu, Wada Takashi, Maruyama Shoichi, Hoshino Junichi |
| 担当区分 | 最終著者 |
| 発行年月 | 2026/05/25 |
| 概要 | BACKGROUND:Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are likely to be effective in patients with anemia in chronic kidney disease (CKD) who are resistant to treatment with erythropoiesis-stimulating agents (ESAs). However, few studies assess HIF-PHIs in patients with elevated ERI who do not yet require hemodialysis.METHODS:This multicenter, prospective, observational study utilized data from the Reach-J study to explore the characteristics of Japanese patients with anemia in CKD (stage G3b-5) who switched from ESAs to HIF-PHIs. We also examined changes in hemoglobin levels following switching.RESULTS:We assessed 447 patients who continued ESA treatment and 34 patients who switched from ESAs to HIF-PHIs (mean age: 74 years). Patients who switched had numerically higher mean erythropoietin resistance index (ERI) and numerically lower hemoglobin than those who continued ESA treatment. Mean hemoglobin levels increased following switching (9.9 g/dL vs. 10.6 g/dL; p = 0.004). After 3 months, hemoglobin levels increased in both high and low ERI subgroups (high ERI: 9.7 g/dL to 11.1 g/dL, low ERI: 10.6 g/dL to 11.8 g/dL). Hemoglobin levels did not notably decrease before or after the start of hemodialysis in two HIF-PHI-treated patients.CONCLUSIONS:Patients who switched to HIF-PHIs had low hemoglobin levels and high ERI compared with those who continued ESA treatment. Both high ERI and low ERI groups had increased hemoglobin levels after switching.TRIAL REGISTRATION:UMIN Clinical Trials Registry (UMIN000022145, registration date: 30 April 2016). |
| DOI | 10.1186/s12882-026-05036-3 |
| PMID | 42185975 |